Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targeting Drug Costs Will Have Minimal Impact On Federal Health Care Spending - Avalere

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent analysis shows that only about 8% of federal Medicare and Medicaid spending goes to brand-name prescription drugs.

You may also be interested in...

Obama Deficit Reduction Plan Takes Aim At Drug Costs, Strengthens IPAB

President Obama's deficit reduction framework borrows ideas from previous spending documents such as the 2012 budget and the fiscal commission report in its cost-cutting recommendations for Medicare.

Three Ways IPAB Can Reduce Drug Costs In Medicare: An Interview With Scott Gottlieb

The Independent Payment Advisory Board is likely to take three approaches to reining in drug costs under Medicare, according to American Enterprise Institute Resident Fellow Scott Gottlieb.

Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?

A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts